Alembic Pharmaceuticals announced that its joint venture Aleor
Dermaceuticals (Aleor) has received final approval from the US Food & Drug
Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Testosterone
Gel, 1.62% (20.25 mg/1.25 gm actuation). The approved ANDA is therapeutically equivalent
to the reference listed drug product (RLD), AndroGel 1.62%, of AbbVie Inc. (AbbVie).
Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) is indicated for replacement therapy
in adult males for conditions associated with a deficiency or absence of endogenous
testosterone: Primary hypogonadism (congenital or acquired) and Hypogonadotropic
hypogonadism (congenital or acquired). Aleor had previously received tentative approval for
this ANDA.
Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) has an estimated market size of US$ 86 million for twelve months ending December 2020 according to IQVIA.
Alembic has a cumulative total of 138 ANDA approvals (122 final approvals and 16 tentative approvals) from USFDA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
